Humanized antibody molecules to CD138 and uses thereof

Patent metadata

Field	Value
Publication number	US-12338291-B2
Application number	US-202016904090-A
Country	US
Kind code	B2
Filing date	Jun 17, 2020
Priority date	Jun 17, 2019
Publication date	Jun 24, 2025
Grant date	Jun 24, 2025

Abstract

Humanized antibody molecules that specifically bind to CD138 are disclosed. The humanized antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

First claim

What is claimed is:

1. A monoclonal anti-CD138 antibody molecule comprising:
(a) a heavy chain variable region (VH), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 380, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 514, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 508; and
(b) a light chain variable region (VL), wherein the VL comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the VL comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 510, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 353, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 354.

2. The antibody molecule of claim 1 , wherein:
(a) the VH comprises the amino acid sequence of SEQ ID NO: 471;
(b) the VL comprises the amino acid sequence of SEQ ID NO: 475; or
(c) both (a) and (b).

3. The antibody molecule of claim 1 , comprising an Fc region.

4. The antibody molecule of claim 1 , comprising:
(a) a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 527;
(b) a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 528; or
(c) both (a) and (b).

5. The antibody molecule of claim 1 , which comprises two VHs and two VLs.

6. An antibody-molecule drug conjugate (ADC) comprising the antibody molecule of claim 1 coupled to a therapeutic agent.

7. A pharmaceutical composition comprising the antibody molecule of claim 1 and a pharmaceutically acceptable carrier.

8. A kit comprising the antibody molecule of claim 1 and instructions for use of the antibody molecule.

9. A container comprising the antibody molecule of claim 1 .

10. The antibody molecule of claim 1 , which is a monovalent antibody molecule or a monospecific antibody molecule.

11. The antibody molecule of claim 1 , which is a humanized antibody molecule.

12. The antibody molecule of claim 1 , which is an IgG antibody.

13. The antibody molecule of claim 1 , which comprises a heavy chain constant region of an IgG chosen from IgG1, IgG2, IgG3, or IgG4.

14. The antibody molecule of claim 1 , which comprises a light chain constant region of a kappa light chain or a lambda light chain.

15. The antibody molecule of claim 1 , which comprises an Fc region comprising one or more mutations to increase the binding affinity to FcRn.

16. The antibody molecule of claim 1 , which comprises an Fc region comprising one or more mutations to increase one or more of half-life, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or antibody-dependent cellular phagocytosis (ADCP).

17. A monoclonal anti-CD138 antibody molecule comprising a VH comprising the amino acid sequence of SEQ ID NO: 471 and a VL comprising the amino acid sequence of SEQ ID NO: 475.

18. A pharmaceutical composition comprising the antibody molecule of claim 17 and a pharmaceutically acceptable carrier.

19. A monoclonal anti-CD138 antibody molecule comprising a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 527 and a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 528.

20. A pharmaceutical composition comprising the antibody molecule of claim 19 and a pharmaceutically acceptable carrier.

21. The antibody molecule of claim 1 , which is a multivalent antibody molecule or a multispecific antibody molecule.

Assignees

• Visterra Inc

Inventors

• Chaganty Bharat
• Ramakrishnan Boopathy
• Adari-Hall Hedy
• Viswanathan Karthik
• Myette James R
• Shriver Zachary
• Wollacott Andrew M

Classifications

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/35

  Valency · CPC title